Back to today’s briefing

Story perspectives

Moderna's Dual Vaccine Shows Promising Results for Adults

5/8/2025

43 7

Summary

Story summary

Moderna's innovative combo vaccine for COVID-19 and flu has demonstrated impressive results in trials with over 8,000 adults aged 50 and up, boasting antibody levels 20-40% higher than current options. With FDA approval anticipated by 2026, this mRNA vaccine promises to streamline the vaccination process, offering hope for a healthier future.

1 of 1

Story summary

Moderna's innovative combo vaccine for COVID-19 and flu has demonstrated impressive results in trials with over 8,000 adults aged 50 and up, boasting antibody levels 20-40% higher than current options. With FDA approval anticipated by 2026, this mRNA vaccine promises to streamline the vaccination process, offering hope for a healthier future.